NewcelX (NCEL) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rocket One (RKTO) has outperformed NewcelX (NCEL) over the past year, losing 59.1% versus a loss of 83.3%. Over five years, RKTO leads with a -97.8% price change compared with -99.7% for NCEL. NewcelX is the larger company by market cap ($17.6 million vs $16.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NCEL | RKTO |
|---|---|---|
| Share price | $3.05 | $0.6493 |
| Market cap | $17.59M | $16.17M |
| 1-day change | -2.09% | +0.50% |
| YTD return | +63.68% | -34.74% |
| 1-year return | -83.32% | -59.11% |
| 5-year return | -99.68% | -97.77% |
| P/E ratio (TTM) | 5.86 | — |
| EPS (TTM) | $0.52 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.60 | $2.45 |
| 52-week low | $1.83 | $0.489 |
| Distance from 52-week high | -83.63% | -73.50% |
| Analyst consensus | none | — |
| Avg. price target upside | +655.34% | — |
| Average volume | 10.28K | 630.66K |
| Shares outstanding | 5.78M | 24.90M |
| Employees | 9 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RKTO has outperformed NCEL by 24.2 percentage points over the past year.
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
NCEL vs RKTO FAQ
Which is bigger, NewcelX or Rocket One?
NewcelX (NCEL) is larger, with a market capitalization of $17.59M compared with $16.17M for Rocket One (RKTO).
Which stock has performed better over the past year, NCEL or RKTO?
RKTO returned -59.11% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are NewcelX and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.